Q-omics provides the consensus-scored SLC22A31 profile across patient tissues and cancer cell-line models. SLC22A31 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC22A31 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SLC22A31 RNA expression shows 11,909 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where SLC22A31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A31 survival associations across molecular data types. SLC22A31 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A31 RNA expression–survival associations across cancer types. High SLC22A31 expression shows unfavorable associations in UVM, KIRC, LUSC, KIRP and COAD, but favorable associations in MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC22A31 RNA expression.
This table summarizes SLC22A31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A31 shows lower tumor expression in LUSC and LUAD and higher tumor expression in THCA, LIHC, BRCA and COAD. The THCA box plot shows higher SLC22A31 RNA expression in tumor versus normal tissue (log2 FC = +6.185, t-test p < 0.001).
This table shows molecular features associated with SLC22A31 in patient tissues and cancer cell lines. In patient samples, SLC22A31 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
